PREVAIL
A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease (ASCVD) Who Are Not Adequately Controlled Despite Maximally Tolerated Lipid-Modifying Therapies
- Stage
- followup
- Medicine
- Obicetrapib
- Population
- ASCVD
- Phase
- III
- First Patient In
- 20 June 2022
- Last Patient In
- 30 April 2024
- Last Patient Last Visit
- 1 November 2026
National Lead
dr. mr. A.J.M. Oude Ophuis
Cardioloog
Study Director
dr. C. van Ofwegen-Hanekamp
Cardioloog
Office Contact
